- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00245453
Outpatient Registry Trial of Respiratory Tract Infections in Adults
July 27, 2015 updated by: CPL Associates
Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT)
To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
To Evaluate the relationship between rate of S. pneumoniae killing in sputum, PK/PD, and clinical response of oral telithromycin and azithromycin in patients with AECB or CAP and to determine if there is a difference in the rates of infection site bacterial killing (as described above) between these 3 antibiotics against penicillin- and erythromycin-resistant S.pneumoniae
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 42240
- Western Kentucky Pulmonary Clinic
-
-
Louisiana
-
Slidell, Louisiana, United States, 70461
- Northshore Research Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients, either males or non-pregnant females, aged 18 to 75 years of age with clinical findings of CAP or AECB who are amenable to serial nasopharyngeal and oropharyngeal sampling and having positive Binax-NOW tests indicating infection with Streptococcus pneumoniae
- Patients with a medical history and clinical findings consistent with a respiratory tract infection. A patient with advanced COPD, repeated exacerbations by history, a BINAX-NOW test consistent with S. pneumoniae and/or proven culture positivity for S. pneumoniae may be enrolled
- All patients (CAP or AECB) must produce purulent sputum and be positive on the Urinary BINAX-NOW assay.
- The female patient of child bearing potential must agree to use an accepted method of contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide and barrier methods, or IUD). The patient must agree to continue with the same method throughout the study.
Exclusion Criteria:
- Baseline sputum cultures known to be negative for S. pneumoniae, or negative urinary BINAX-NOW.
- Patients with a microbiologically documented pathogen known prior to inclusion to be resistant to any of the study medications.
- History of hypersensitivity to macrolides, azalides, ketolide antibiotics or history of serious hypersensitivity reaction to any drug.
- Pre-existing impaired hepatic function or impaired renal function CCL <20ml/min
- Patients who will require on-study treatment with medications known to have contraindicated drug interactions with telithromycin
- Treatment with more than one dose of an antimicrobial prior to entry into the study
Others as per protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1 Azithromycin
|
250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
|
Active Comparator: 2 Clarythromycin
|
500 mg extended release tablets; 2 tablets QD for 7 days
|
Active Comparator: 3 Telithromycin
|
400 mg tablets; 2 tablets once daily (QD) for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to bacterial eradication
Time Frame: 11-18 days
|
11-18 days
|
Bacteriologic outcome
Time Frame: 11-18 days
|
11-18 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jerome J Schentag, Pharm.D., State University of New York at Buffalo
- Study Director: Joseph Paladino, Pharm.D., State University of New York at Buffalo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
October 26, 2005
First Submitted That Met QC Criteria
October 26, 2005
First Posted (Estimate)
October 28, 2005
Study Record Updates
Last Update Posted (Estimate)
July 28, 2015
Last Update Submitted That Met QC Criteria
July 27, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Pneumonia
- Respiratory Tract Infections
- Pneumonia, Bacterial
- Bronchitis
- Bronchitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Clarithromycin
- Azithromycin
- Telithromycin
Other Study ID Numbers
- HMR3647A6004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Bacterial
-
Evopoint Biosciences Inc.RecruitingHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaUnited States, Spain, France, Israel
-
Merck Sharp & Dohme LLCCompletedHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial PneumoniaMexico, Brazil, China, France, Philippines, Romania, Russian Federation, Ukraine
-
Omnix Medical LtdNot yet recruitingVentilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia
-
Massachusetts General HospitalUnited States Agency for International Development (USAID)UnknownInfections - Bacterial | Pneumonia - BacterialPakistan
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Zai Lab (Hong Kong), Ltd.RecruitingCommunity-acquired Bacterial PneumoniaUnited States
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Fundación Pública Andaluza para la gestión de la...European CommissionCompletedVentilator-associated Bacterial PneumoniaSpain, Italy, Greece
-
Albany Medical CollegeForest Laboratories; Albany College of Pharmacy and Health SciencesCompletedCommunity Acquired Bacterial PneumoniaUnited States
Clinical Trials on azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedBacterial Infections
-
Sheba Medical CenterUnknown
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States